Document is current
Any future updates will be listed below
-
Authors
Nachmias, Boaz https://orcid.org/0000-0002-7341-2167
Khan, Dilshad H.
Voisin, Veronique
Mer, Arvind S.
Thomas, Geethu Emily
Segev, Nadav
St-Germain, Jonathan
Hurren, Rose
Gronda, Marcela
Botham, Aaron
Wang, Xiaoming
Maclean, Neil
Seneviratne, Ayesh K.
Duong, Nathan https://orcid.org/0000-0001-7171-5554
Xu, Changjiang
Arruda, Andrea
Orouji, Elias https://orcid.org/0000-0002-7413-1383
Algouneh, Arash
Hakem, Razqallah
Shlush, Liran
Minden, Mark D.
Raught, Brian
Bader, Gary D.
Schimmer, Aaron D. https://orcid.org/0000-0003-4023-3899
-
Funding
Funding for this research was provided by:
Israel Science Foundation (2221.21)
Israel Cancer Association (2022.1518)
Gouvernement du Canada | Canadian Institutes of Health Research (154282)
Ontario Institute for Cancer Research
Princess Margaret Cancer Foundation
- License Information
-
More Information
Article History
Received: 19 June 2021
Revised: 6 January 2022
Accepted: 26 January 2022
First Online: 12 February 2022
Competing interests
: ADS has received research funding from Takeda Pharmaceuticals and Medivir AB, and consulting fees/honorarium from Takeda, BMS, Novartis, Jazz, and Otsuka Pharmaceuticals. ADS is named on a patent application for the use of DNT cells to treat AML.
